APO RESEARCH · REPORT
Amyotrophic Lateral Sclerosis (ALS) Treatment
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
Product & engineering
Understand the product.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
Selected research
Industry Research
Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Research Report 2026
Market perspective
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
Read the full market overview
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.
Report Scope
This report quantifies the global Amyotrophic Lateral Sclerosis (ALS) Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Amyotrophic Lateral Sclerosis (ALS) Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Company
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Type
Riluzole
Edaravone (Radicava)
Other
Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application
Hospital
Drugs Store
Other
Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS) Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Riluzole
- Edaravone (Radicava)
- Other
Applications
- Hospital
- Drugs Store
- Other
Companies covered
- Mitsubishi Tanabe Pharma
- Sanofi
- Mylan Pharma
- Apotex
- Glemark Generics
- Covis Pharma
- Sun Pharma
- Lunan Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Riluzole
- 2.2.3 Edaravone (Radicava)
- 2.2.4 Other
- 2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Drugs Store
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Type
- 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2027-2032)
4 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Application
- 4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Perspective (2021-2032)
- 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Region
- 5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
- 5.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
- 5.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
- 5.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
- 5.3.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue
- 6.1.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment Head Office and Area Served
- 6.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players, Product Type & Application
- 6.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Manufacturers Established Date
- 6.6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
- 7.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
- 7.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
- 8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
- 8.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
- 10.2 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
- 10.4 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Mitsubishi Tanabe Pharma
- 12.1.1 Mitsubishi Tanabe Pharma Company Information
- 12.1.2 Mitsubishi Tanabe Pharma Business Overview
- 12.1.3 Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2021-2026)
- 12.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
- 12.1.5 Mitsubishi Tanabe Pharma Recent Developments
- 12.2 Sanofi
- 12.2.1 Sanofi Company Information
- 12.2.2 Sanofi Business Overview
- 12.2.3 Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2021-2026)
- 12.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
- 12.2.5 Sanofi Recent Developments
- 12.3 Mylan Pharma
- 12.3.1 Mylan Pharma Company Information
- 12.3.2 Mylan Pharma Business Overview
- 12.3.3 Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2021-2026)
- 12.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
- 12.3.5 Mylan Pharma Recent Developments
- 12.4 Apotex
- 12.4.1 Apotex Company Information
- 12.4.2 Apotex Business Overview
- 12.4.3 Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2021-2026)
- 12.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
- 12.4.5 Apotex Recent Developments
- 12.5 Glemark Generics
- 12.5.1 Glemark Generics Company Information
- 12.5.2 Glemark Generics Business Overview
- 12.5.3 Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2021-2026)
- 12.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
- 12.5.5 Glemark Generics Recent Developments
- 12.6 Covis Pharma
- 12.6.1 Covis Pharma Company Information
- 12.6.2 Covis Pharma Business Overview
- 12.6.3 Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2021-2026)
- 12.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
- 12.6.5 Covis Pharma Recent Developments
- 12.7 Sun Pharma
- 12.7.1 Sun Pharma Company Information
- 12.7.2 Sun Pharma Business Overview
- 12.7.3 Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2021-2026)
- 12.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
- 12.7.5 Sun Pharma Recent Developments
- 12.8 Lunan Pharma
- 12.8.1 Lunan Pharma Company Information
- 12.8.2 Lunan Pharma Business Overview
- 12.8.3 Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2021-2026)
- 12.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
- 12.8.5 Lunan Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst